EyeGene said on Friday in a public filing that its phase 2 clinical trial of EG-Myocin, a drug candidate for the treatment of myocardial ischemia and reperfusion injury, failed to show statistically significant changes in myocardial infarction size. The study explored the effectiveness and safety of
Starting in October, the reimbursement standards for the spinal muscular atrophy (SMA) drugs Spinraza (nusinersen) and Evrysdi (risdiplam) will be expanded and newly established.The Ministry of Health and Welfare (MOHW) issued an administrative notice on the “Partial amendment to the details (pharma
Celltrion Healthcare said on Monday it won bids in major European countries for three of its anti-cancer biosimilars, Truxima (ingredient: rituximab), Herzuma (ingredient: trastuzumab), and Vegzelma (ingredient: bevacizumab), since switching to direct sales. On the same day, Celltrion also announced
EuBiologics said on Friday that it signed a memorandum of understanding (MOU) with South African vaccine manufacturer, Biovac, to supply its meningococcal pentavalent vaccine to the local market and transfer technology to produce finished doses. EuBiologics' meningococcal pentavalent conjugate vacci
Viatris Korea announced results from a survey involving 963 diabetic patients with neuropathic pain (NeP) from Korea, Italy, Spain, Malaysia and Mexico, during a press conference on Thursday.The survey was designed to learn more about the impact of NeP and the unmet needs of people living with diabe
EuBiologics said on Thursday that it received an award letter from the United Nations Children's Fund (UNICEF) for the delivery of 49.3 million doses of its oral cholera vaccine in 2024, valued at approximately $99 million. This order surpasses the company's 51.2 billion won in cholera vaccine sales
Organon Korea, a spin-off from MSD Korea entering its third year, takes the lead in raising awareness and improving the environment for women's health issues, including contraception and infertility, establishing itself as a company specializing in women's health.On Wednesday, Organon Korea held the
Biogen, maker of the spinal muscular atrophy (SMA) drug Spinraza (nusinersen), and Roche, maker of Evrysdi (risdiplam), recently reached a dramatic agreement with the government by even extending drug price negotiations.Now, the patients are also shifting their attention to dosing standardsAccording
Alteogen, a company specializing in next-generation biobetters, said on Tuesday that it obtained a U.S. patent regarding its proprietary antibody technology.In particular, the patent covers the technology of the antibody which specifically bind to the folate receptor alpha (FOLR1). The patent was gr
Novartis Korea said it held the seventh emotional support program, CHEERYOU, for patients with rare and intractable diseases in collaboration with the Korean Organization for Rare Diseases (KORD) at the Pine Valley Glamping Site in Pocheon, Gyeonggi Province, last Friday.The CHEERYOU campaign, a fla
ST Pharm said it has taken its first step towards becoming the global leader in the oligonucleotide contract development and manufacturing organization (CDMO) domain with the groundbreaking ceremony for its second oligonucleotide facility on Monday.The new plant will be located in Ansan, Gyeonggi Pr
As Korean and foreign pharmaceutical and biotechnology companies are stepping up to develop antibody-drug conjugates (ADCs), Daiichi Sankyo presented its outlook on the future direction of ADC development.Daiichi Sankyo co-developed Enhertu (trastuzumab deruxtecan), a new generation ADC anticancer d
PharmAbcine received approval from the Australian Human Research Ethics Committees (HRECs) last Friday to conduct a phase 1a/b clinical trial of PMC-309.PMC-309 is a VISTA-targeted immuno-oncology agent for patients with advanced or metastatic solid tumors.According to PharmAbcine, PMC-309 is an IgG
Sanofi Aventis Korea is aiming to revolutionize the treatment landscape for Pompe disease patients with the reimbursement of its novel enzyme replacement therapy, Nexviazyme (ingredient: avalglucosidase alfa-ngpt), from Sep. 1, the company said.Sanofi-Aventis Korea organized a press conference at th
In the wake of revelations that a key ingredient could transform into tumor-inducing kidney cells, Kolon Life Science's osteoarthritis gene therapy, Invossa-K Inj., which had its product license revoked, has been linked to numerous reported cases of tumors in patients after administration.According
Climate change has had widespread impacts on the planet and its consequences to human health are escalating, presenting challenges for vaccine manufacturers, researchers, and epidemiologists alike. Dr. Adamberage Ruklanthi de Alwis, Deputy Director of the Center for Outbreak Preparedness at Duke-NUS
Moderna announced its collaboration with Korea University Medical Center and Chosun University Industry-Academic Cooperation Foundation on Friday to expand its global public health initiative, mRNA Access, in Korea.The initiative aims to expedite the vaccine development process worldwide using Moder
Daewoong Therapeutics, an affiliate of the Daewoong Group, said on Friday that it received approval from the Ministry of Food and Drug Safety (MFDS) for a phase 1 clinical trial plan for its diabetic retinopathy candidate, DWRX2008. DWRX2008 is a diabetic retinopathy treatment that Daewoong Therapeu
A local doctor expressed his enthusiasm that the reimbursement of Pfizer Korea's Ngenla (ingredient: Somatropin), a once-weekly growth hormone drug, will enhance compliance among adolescent patients.At a press conference held to mark the reimbursement at the Koreana Hotel in Seoul on Thursday, Profe
Hanmi Pharm has suggested that the company could develop HM15912, its short bowel syndrome treatment candidate developed as a once-monthly dosage form, as a treatment for another rare disease, graft-versus-host disease (GVHD).Hanmi said Thursday that it presented two posters on the research results